Background There are few evidences about the value of drug eluting stent in patients with ST-segment elevationmyocardial infarction (STEMI).We prospectively designed a randomized controlled trial to compare the safety andefficacy of Firebird sirolimus eluting stent (Firebird stent) and bare metal stent (BMS).Methods Patients with STEMI enrolled during one year period were randomized to undergo implantation of Firebirdstent or BMS,and clinical and angiographic follow-up.The primary endpoint of the present study was in-lesion late lumenloss (LLL) at 6 months,and secondary endpoint includes stent thrombosis and major adverse cardiac events (MACE) at6 months.Results During one year period,156 patients were randomized into the Firebird stent group (101 patients with anaverage age of 57.8 years) or the BMS group (55 patients with 59.7 years on average).Six-month angiographic follow-upwas available in 66.3% and 63.7% of patients assigned to Firebird stent and BMS,respectively.At 6-month follow-up,mortality,target vessel revascularization (rVR) and MACE were 2.0%,6.9% and 9.9% in the Firebird stent group,while3.6%,30.9% and 36.4% in the BMS group (P<0.05).Subacute thrombosis occurred in 1 patient in both groups,respectively.The mean LLL was 0.18 mm in the Firebird stent group versus 0.72 mm in the BMS group.Conclusion Implantation of Firebird sirolimus eluting stent for STEMI may greatly reduce TVR and MACE at 6months with low incidence of acute/subacute stent thrombosis compared with BMS. Background There are few evidences about the value of drug eluting stent in patients with ST-segment elevationmyocardial infarction (STEMI). We prospectively designed a randomized controlled trial to compare the safety andefficacy of Firebird sirolimus eluting stent (Firebird stent) and bare metal stent BMS). Patients Patients with STEMI enrolled during one year period were randomized to undergo implantation of Firebirdstent or BMS, and clinical and angiographic follow-up. The primary endpoint of the present study was in-lesion late lumenloss (LLL) at 6 months, and secondary endpoints included stent thrombosis and major adverse cardiac events (MACE) at 6 months. Results During one year period, 156 patients were randomized into the Firebird stent group (101 patients with an aragerage age of 57.8 years) or the BMS group (55 patients with 59.7 years on average). Six-month angiographic follow-up was available in 66.3% and 63.7% of patients assigned to Firebird stent and BMS, respectively. At 6-month follo The levels of w-up, mortality, target vessel revascularization (rVR) and MACE were 2.0%, 6.9% and 9.9% in the Firebird stent group while 3.6%, 30.9% and 36.4% in the BMS group thrombosis occurred in 1 patient in both groups, respectively. The mean LLL was 0.18 mm in the Firebird stent group versus 0.72 mm in the BMS group. Confound Implantation of Firebird sirolimus eluting stent for STEMI may greatly reduce TVR and MACE at 6months with low incidence of acute / subacute stent thrombosis compared with BMS.